Genzyme targets Zydus in patent infringement claim

Genzyme has sued Zydus Pharmaceuticals in a lawsuit that claims that the company has infringed two of its patents.

The case, filed at the US District Court for the District of Delaware, came after Zydus applied for an Abbreviated New Drug Application at the US Food and Drug Administration.

Zydus is seeking approval to market a generic version of Mozobil (plerixafor injection), a drug used to enhance mobilisation of haematopoietic stem cells.

According to the complaint, Zydus plans to market the generic in the US before the two patents in suit expire.

The patents, US numbers 7,897,590 and 6,987,102, expire on July 22, 2023.